WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO: SOBI) today announced positive topline results from the
Philadelphia, PA, August 5, 2024 – NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3
– Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 – NodThera, a leading clinical-stage biotech delivering a paradigm
Edinburgh, UK, 22 July 2024: Lario Therapeutics (‘Lario’, or ‘the Company’), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, today announced
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK,: Harness Therapeutics,
Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis Pharmaceuticals
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop
Edinburgh, UK – Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and chronic inflammatory disorders,